 Michele Loi
Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pleural Effusion | 1 | 2021 | 47 | 0.760 |
Why?
| | Coronavirus | 1 | 2020 | 40 | 0.680 |
Why?
| | Renal Insufficiency | 1 | 2021 | 137 | 0.680 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 79 | 0.670 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2018 | 25 | 0.630 |
Why?
| | Tranexamic Acid | 1 | 2018 | 40 | 0.610 |
Why?
| | Neutrophil Activation | 1 | 2018 | 94 | 0.610 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 292 | 0.600 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 519 | 0.530 |
Why?
| | Pandemics | 2 | 2023 | 1335 | 0.520 |
Why?
| | Seizures | 1 | 2018 | 344 | 0.520 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 344 | 0.490 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.490 |
Why?
| | Blood Preservation | 1 | 2018 | 263 | 0.490 |
Why?
| | Antiviral Agents | 1 | 2020 | 649 | 0.480 |
Why?
| | Erythrocytes | 1 | 2018 | 589 | 0.450 |
Why?
| | Heart Failure | 1 | 2021 | 1964 | 0.320 |
Why?
| | Child | 9 | 2023 | 18503 | 0.220 |
Why?
| | Femoral Vein | 1 | 2020 | 28 | 0.180 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 193 | 0.180 |
Why?
| | Immunomodulation | 1 | 2020 | 85 | 0.170 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 81 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 234 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 269 | 0.160 |
Why?
| | Blood Buffy Coat | 1 | 2018 | 5 | 0.160 |
Why?
| | Methods | 1 | 2018 | 58 | 0.160 |
Why?
| | Filtration | 1 | 2018 | 62 | 0.150 |
Why?
| | Solutions | 1 | 2018 | 150 | 0.150 |
Why?
| | Chordoma | 1 | 2017 | 13 | 0.140 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 26 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.140 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 38 | 0.140 |
Why?
| | Anticoagulants | 1 | 2020 | 549 | 0.130 |
Why?
| | Humans | 13 | 2023 | 115741 | 0.120 |
Why?
| | Immunization, Passive | 2 | 2023 | 80 | 0.100 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2022 | 147 | 0.090 |
Why?
| | Retinoids | 1 | 2009 | 31 | 0.080 |
Why?
| | Infant | 4 | 2023 | 7979 | 0.080 |
Why?
| | Inflammation | 1 | 2018 | 2500 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2009 | 143 | 0.080 |
Why?
| | Critical Illness | 2 | 2023 | 645 | 0.070 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 195 | 0.070 |
Why?
| | Streptococcus pyogenes | 1 | 2023 | 33 | 0.060 |
Why?
| | Melanoma | 1 | 2009 | 651 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2023 | 12633 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 57 | 0.050 |
Why?
| | Male | 3 | 2023 | 56050 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1361 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2023 | 308 | 0.050 |
Why?
| | Blood Transfusion | 1 | 2023 | 277 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 6276 | 0.040 |
Why?
| | Child, Preschool | 2 | 2023 | 9138 | 0.040 |
Why?
| | Acute Disease | 1 | 2020 | 914 | 0.040 |
Why?
| | Rhabdomyoma | 1 | 2017 | 10 | 0.040 |
Why?
| | Angiomyolipoma | 1 | 2017 | 18 | 0.040 |
Why?
| | Ultrasonography | 1 | 2020 | 642 | 0.040 |
Why?
| | Heart Neoplasms | 1 | 2017 | 50 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 526 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 286 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4116 | 0.030 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 326 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2586 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4949 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2023 | 5061 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 2990 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2017 | 761 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 8702 | 0.020 |
Why?
| | Retinoid X Receptors | 1 | 2009 | 39 | 0.020 |
Why?
| | Benzoates | 1 | 2009 | 38 | 0.020 |
Why?
| | Tetrahydronaphthalenes | 1 | 2009 | 31 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 9162 | 0.020 |
Why?
| | PPAR gamma | 1 | 2009 | 185 | 0.020 |
Why?
| | Ligands | 1 | 2009 | 569 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 544 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2009 | 704 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3122 | 0.020 |
Why?
| | Adolescent | 1 | 2023 | 17922 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 638 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2207 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 2751 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2194 | 0.010 |
Why?
| | Adult | 1 | 2023 | 30789 | 0.010 |
Why?
| | Female | 1 | 2023 | 60018 | 0.010 |
Why?
| | Mice | 1 | 2009 | 15052 | 0.010 |
Why?
| | Animals | 1 | 2009 | 32104 | 0.000 |
Why?
|
|
Loi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|